Annual Revenue (as of Sep 30)
Blueprint Medicines (NASDAQ:BPMC) reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Blueprint Medicines beat estimated earnings by 10.44%, reporting an EPS of $-2.23 versus an estimate of $-2.49.
Revenue was up $41.79 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.45 which was followed by a 6.06% increase in the share price the next day.
Here's a look at Blueprint Medicines's past performance:
|Quarter||Q2 2022||Q1 2022||Q4 2021||Q3 2021|
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Analyze the earnings history of Blueprint Medicines using advanced sorting and filters.
When is Blueprint Medicines (NASDAQ:BPMC) reporting earnings?
Blueprint Medicines (BPMC) is scheduled to report earnings on February 15, 2023. The last reported earnings were for reported on November 1, 2022 for Q3.
What were the latest earnings per share (EPS) for Blueprint Medicines (NASDAQ:BPMC)?
The Actual EPS was $-1.23, which missed the estimate of $0.00.
What were Blueprint Medicines’s (NASDAQ:BPMC) revenues?
The Actual Revenue was $1.6M, which beat the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.